Rising Incidence of Acute Hospital Admissions due to Gout

Mark D. Russell; Mark Yates; Katie Bechman; Andrew I. Rutherford; Sujith Subesinghe; Peter Lanyon; James B. Galloway

doi:10.3899/jrheum.190257

Rising Incidence of Acute Hospital Admissions due to Gout

Mark D. Russell, Mark Yates, Katie Bechman, Andrew I. Rutherford, Sujith Subesinghe, Peter Lanyon, James B. Galloway

Inflammation Biology

Research output: Contribution to journal › Article › peer-review

22 Citations (Scopus)

Abstract

Objective. To describe trends in acute hospital admissions due to gout in England, with rheumatoid arthritis (RA) as a comparator, alongside prescribing trends for common gout medications. Methods. An ecological study was performed using UK National Health Service (NHS) Digital Hospital Episode Statistics data to calculate the incidence of unplanned admissions with primary diagnoses of gout or RA in adults in England between April 2006 and March 2017. NHS Digital Community Prescription data for allopurinol, febuxostat, and colchicine were considered over a similar period. Results. The incidence of unplanned gout admissions increased by 58.4% over the study period, from 7.9 admissions per 100,000 population in 2006/07 to 12.5 admissions per 100,000 population in 2016/17 (p < 0.0001). Gout admissions increased as a proportion of all hospital admissions, and accounted for 349,768 bed-days cumulatively. Unplanned RA admissions halved over the study period, from 8.6 admissions per 100,000 population in 2006/07 to 4.3 admissions per 100,000 population in 2016/17 (p < 0.0001). Community prescriptions dispensed for allopurinol and colchicine have increased by 71.4% and 165.6%, respectively, since 2006 (p < 0.0001). Febuxostat prescriptions have increased 20-fold since 2010 (p < 0.0001), when prescription data became available. Conclusion. Acute gout admissions in England increased between 2006 and 2017, accompanied by increasing prescription of gout therapies. Acute admissions due to RA halved over the same time period. These data call for aggressive target-driven therapy for this highly treatable disease. (First Release February 15 2020; J Rheumatol 2020;47:619-23; doi:10.3899/jrheum.190257).

Original language	English
Pages (from-to)	619-623
Number of pages	5
Journal	Journal of Rheumatology
Volume	47
Issue number	4
DOIs	https://doi.org/10.3899/jrheum.190257
Publication status	Published - 1 Apr 2020

Keywords

Epidemiology
Gout
Health services research
Rheumatoid arthritis

Access to Document

10.3899/jrheum.190257

Cite this

@article{3a99b3c3bf644acb8f980bda5ddfadf7,

title = "Rising Incidence of Acute Hospital Admissions due to Gout",

abstract = "Objective. To describe trends in acute hospital admissions due to gout in England, with rheumatoid arthritis (RA) as a comparator, alongside prescribing trends for common gout medications. Methods. An ecological study was performed using UK National Health Service (NHS) Digital Hospital Episode Statistics data to calculate the incidence of unplanned admissions with primary diagnoses of gout or RA in adults in England between April 2006 and March 2017. NHS Digital Community Prescription data for allopurinol, febuxostat, and colchicine were considered over a similar period. Results. The incidence of unplanned gout admissions increased by 58.4% over the study period, from 7.9 admissions per 100,000 population in 2006/07 to 12.5 admissions per 100,000 population in 2016/17 (p < 0.0001). Gout admissions increased as a proportion of all hospital admissions, and accounted for 349,768 bed-days cumulatively. Unplanned RA admissions halved over the study period, from 8.6 admissions per 100,000 population in 2006/07 to 4.3 admissions per 100,000 population in 2016/17 (p < 0.0001). Community prescriptions dispensed for allopurinol and colchicine have increased by 71.4% and 165.6%, respectively, since 2006 (p < 0.0001). Febuxostat prescriptions have increased 20-fold since 2010 (p < 0.0001), when prescription data became available. Conclusion. Acute gout admissions in England increased between 2006 and 2017, accompanied by increasing prescription of gout therapies. Acute admissions due to RA halved over the same time period. These data call for aggressive target-driven therapy for this highly treatable disease. (First Release February 15 2020; J Rheumatol 2020;47:619-23; doi:10.3899/jrheum.190257).",

keywords = "Epidemiology, Gout, Health services research, Rheumatoid arthritis",

author = "Russell, {Mark D.} and Mark Yates and Katie Bechman and Rutherford, {Andrew I.} and Sujith Subesinghe and Peter Lanyon and Galloway, {James B.}",

year = "2020",

month = apr,

day = "1",

doi = "10.3899/jrheum.190257",

language = "English",

volume = "47",

pages = "619--623",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "4",

}

TY - JOUR

T1 - Rising Incidence of Acute Hospital Admissions due to Gout

AU - Russell, Mark D.

AU - Yates, Mark

AU - Bechman, Katie

AU - Rutherford, Andrew I.

AU - Subesinghe, Sujith

AU - Lanyon, Peter

AU - Galloway, James B.

PY - 2020/4/1

Y1 - 2020/4/1

N2 - Objective. To describe trends in acute hospital admissions due to gout in England, with rheumatoid arthritis (RA) as a comparator, alongside prescribing trends for common gout medications. Methods. An ecological study was performed using UK National Health Service (NHS) Digital Hospital Episode Statistics data to calculate the incidence of unplanned admissions with primary diagnoses of gout or RA in adults in England between April 2006 and March 2017. NHS Digital Community Prescription data for allopurinol, febuxostat, and colchicine were considered over a similar period. Results. The incidence of unplanned gout admissions increased by 58.4% over the study period, from 7.9 admissions per 100,000 population in 2006/07 to 12.5 admissions per 100,000 population in 2016/17 (p < 0.0001). Gout admissions increased as a proportion of all hospital admissions, and accounted for 349,768 bed-days cumulatively. Unplanned RA admissions halved over the study period, from 8.6 admissions per 100,000 population in 2006/07 to 4.3 admissions per 100,000 population in 2016/17 (p < 0.0001). Community prescriptions dispensed for allopurinol and colchicine have increased by 71.4% and 165.6%, respectively, since 2006 (p < 0.0001). Febuxostat prescriptions have increased 20-fold since 2010 (p < 0.0001), when prescription data became available. Conclusion. Acute gout admissions in England increased between 2006 and 2017, accompanied by increasing prescription of gout therapies. Acute admissions due to RA halved over the same time period. These data call for aggressive target-driven therapy for this highly treatable disease. (First Release February 15 2020; J Rheumatol 2020;47:619-23; doi:10.3899/jrheum.190257).

AB - Objective. To describe trends in acute hospital admissions due to gout in England, with rheumatoid arthritis (RA) as a comparator, alongside prescribing trends for common gout medications. Methods. An ecological study was performed using UK National Health Service (NHS) Digital Hospital Episode Statistics data to calculate the incidence of unplanned admissions with primary diagnoses of gout or RA in adults in England between April 2006 and March 2017. NHS Digital Community Prescription data for allopurinol, febuxostat, and colchicine were considered over a similar period. Results. The incidence of unplanned gout admissions increased by 58.4% over the study period, from 7.9 admissions per 100,000 population in 2006/07 to 12.5 admissions per 100,000 population in 2016/17 (p < 0.0001). Gout admissions increased as a proportion of all hospital admissions, and accounted for 349,768 bed-days cumulatively. Unplanned RA admissions halved over the study period, from 8.6 admissions per 100,000 population in 2006/07 to 4.3 admissions per 100,000 population in 2016/17 (p < 0.0001). Community prescriptions dispensed for allopurinol and colchicine have increased by 71.4% and 165.6%, respectively, since 2006 (p < 0.0001). Febuxostat prescriptions have increased 20-fold since 2010 (p < 0.0001), when prescription data became available. Conclusion. Acute gout admissions in England increased between 2006 and 2017, accompanied by increasing prescription of gout therapies. Acute admissions due to RA halved over the same time period. These data call for aggressive target-driven therapy for this highly treatable disease. (First Release February 15 2020; J Rheumatol 2020;47:619-23; doi:10.3899/jrheum.190257).

KW - Epidemiology

KW - Gout

KW - Health services research

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85082979678&partnerID=8YFLogxK

U2 - 10.3899/jrheum.190257

DO - 10.3899/jrheum.190257

M3 - Article

C2 - 31523046

AN - SCOPUS:85082979678

SN - 0315-162X

VL - 47

SP - 619

EP - 623

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 4

ER -

Rising Incidence of Acute Hospital Admissions due to Gout

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this